Why Synthetic Cohorts Undermine Real-World Evidence

Real patient data is longitudinal, incomplete, and contains confounding variables. Synthetic generators produce statistically perfect, clean cohorts that fail to model the noise inherent in clinical practice. This leads to models that perform well on synthetic test sets but fail in production.

• Amplifies existing biases from the source dataset.
• Eliminates informative missingness patterns critical for causal inference.
• Creates an illusion of robustness that evaporates upon deployment.

RWE is most valuable for understanding rare outcomes and adverse events. Generative models like GANs and diffusion models learn to replicate the central tendency of their training data, making them inherently poor at synthesizing low-probability, high-impact scenarios.

• Fails to model novel disease progressions or treatment responses.
• Blinds risk models to black swan events in financial or clinical data.
• Reliance on synthetic data for risk assessment creates dangerous model drift.

Synthetic data inherits the inscrutability of the generative model that created it. This compounds the explainability problem, making it impossible for regulators to audit data provenance or understand causal relationships. This violates core tenets of frameworks like AI TRiSM and the EU AI Act.

• Impossible to perform meaningful bias/fairness audits.
• Creates an un-auditable chain from raw data to model decision.
• Stalls innovation in heavily regulated industries awaiting validation frameworks.

The answer is not to abandon synthetic data, but to deploy it within a rigorous, multi-layered validation strategy. This involves using synthetic data for stress-testing and augmentation while anchoring all causal conclusions in carefully curated real-world data.

• Deploy in 'Shadow Mode' to compare synthetic vs. real-world model performance.
• Use for generating adversarial examples to improve model robustness.
• Anchor to high-fidelity real data for all primary efficacy endpoints.

Move beyond generative models that learn correlations. Invest in Causal AI and structural causal models that explicitly encode domain expertise and known biological/financial mechanisms. This allows for the principled generation of counterfactual data that respects underlying causal graphs.

• Models disease progression and treatment response as time-series.
• Preserves domain-specific nuance (e.g., drug-drug interactions).
• Enables valid what-if scenario analysis for trial design.

For true privacy compliance, generate synthetic data within Confidential Computing enclaves on sovereign, geopatriated infrastructure. This turns synthetic data from a liability into a strategic asset for Sovereign AI, enabling local innovation without cross-border data transfer risks.

• Integrates with Privacy-Enhancing Tech (PET) like differential privacy.
• Enables federated learning across institutions without sharing raw data.
• Becomes a core component of regional AI stacks compliant with local laws.

Real-world patient data is longitudinal, incomplete, and full of confounding variables. Synthetic cohorts are often generated to be statistically 'clean,' stripping out the very noise and missingness that define real-world evidence. This creates models that perform well on paper but fail to generalize to actual patient populations.

• Key Failure: Models trained on synthetic data show ~30-40% lower accuracy when validated on real-world holdout sets.
• Root Cause: Generative models optimize for distributional similarity, not causal fidelity or the complex temporal dependencies of chronic disease.

Health outcomes are a sequence of events. Synthetic data generators, especially tabular models, often fail to preserve the longitudinal integrity of patient journeys. They create statistically plausible snapshots that lack the causal progression of disease and treatment.

• Key Failure: Synthetic time-series data lacks predictive power for readmission risk or treatment adherence.
• Root Cause: Most synthesis techniques treat each visit or measurement as an independent sample, destroying the narrative of care. This is a core challenge for our work in Precision Medicine and Genomic AI.

Synthetic data does not solve bias; it replicates and often amplifies the biases present in the source dataset. Furthermore, generative models like GANs can create spurious correlations—statistical artifacts that don't exist in nature—which become 'facts' for downstream AI models.

• Key Failure: A model trained on synthetic financial data for fraud detection can show >50% higher false positive rates for underrepresented demographic groups.
• Root Cause: The generator's loss function prioritizes overall fidelity, not subgroup fairness or the elimination of proxy variables. This directly impacts AI TRiSM compliance.

Move beyond distribution-matching to synthesis that encodes domain knowledge and causal graphs. This involves building structural causal models (SCMs) with expert clinicians or quants to define relationships before generation, ensuring synthetic data respects known medical or financial mechanics.

• Key Benefit: Produces cohorts usable for counterfactual reasoning and what-if analysis.
• Implementation: Integrates with Digital Twins for clinical trials, creating in-silico patients that behave according to biological first principles.

Instead of centralizing raw data to train a single generator, train lightweight synthesis models locally within Confidential Computing enclaves at each hospital or bank. Share only the model parameters or generated statistics to create a global, privacy-safe cohort.

• Key Benefit: Eliminates the need for cross-border data transfer, aligning with Sovereign AI and GDPR requirements.
• Implementation: This is the technical foundation for collaborative projects in Fintech Fraud Detection without exposing any single institution's customer data.

Treat synthetic data validation as a continuous, adversarial process. Deploy a discriminator model trained to distinguish real from synthetic records. If it succeeds, the synthetic data is flawed. Iterate until the discriminator fails, ensuring the synthetic cohort is indistinguishable for analytical purposes.

• Key Benefit: Creates a rigorous, automated benchmark for statistical equivalence required by regulators.
• Implementation: This is a core MLOps practice, integrating validation into the CI/CD pipeline for any model reliant on synthetic training data, a necessity for AI-Powered CRM and risk modeling systems.